Lomibuvir (VX 222; VCH 222)

Alias: TD-4208; TD4208; GSK-1160724; GSK-1160724; TD 4208; GSK1160724; trade name: Yupelri; TD-4208; GSK 1160724
Cat No.:V0726 Purity: ≥98%
Lomibuvir (also called VX-22; S-1480; VCH222; VX22; S1480; VX222; VCH-222; VX-222) is a novel, potent and selective non-nucleoside inhibitor/NNI of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase with IC50s in the range of 0.94-1.2 μM.
Lomibuvir (VX 222; VCH 222) Chemical Structure CAS No.: 1026785-59-0
Product category: HCV Protease
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
2mg
5mg
10mg
25mg
50mg
100mg
250mg
Other Sizes

Other Forms of Lomibuvir (VX 222; VCH 222):

  • Lomibuvir (VX-222)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Lomibuvir (also called VX-22; S-1480; VCH222; VX22; S1480; VX222; VCH-222; VX-222) is a novel, potent and selective non-nucleoside inhibitor/NNI that targets the NS5B RNA-dependent RNA polymerase of the hepatitis C virus (HCV), with IC50 values ranging from 0.94 to 1.2 μM. For the treatment of chronic HCV and chronic HCV infections, it has been studied in clinical trials. In patients with genotype 1 HCV infection who were chronically infected, VX-222 showed significant reductions in plasma HCV RNA in phase 1 and 2 clinical trials, indicating effective antiviral efficacy.

Biological Activity I Assay Protocols (From Reference)
Targets
HCV NS5B 1a (IC50 = 0.94 μM); HCV NS5B 1b (IC50 = 1.2 μM)
ln Vitro
VX-222 attaches itself to the HCV RNA-dependent RNA polymerase's thumb II allosteric pocket. With an IC50 of 0.94 and 1.2 μM, respectively, VX-222 shows non-competitive and selective inhibition in HCV NS5B of genotypes 1a and 1b. Subgenomic HCV genotypes 1a and 1b are specifically inhibited by VX-222, with EC50 values of 22.3 and 11.2 nM, respectively. (Source: ) Similarly, VX-222 inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5 nM, according to a recent study. While having little to no effect on de novo-initiated RNA synthesis, VX-222 preferentially inhibits primer-dependent RNA synthesis.
ln Vivo
VCH-222 exhibits fine pharmacokinetic properties in rats and dogs, such as low total body clearance, excellent oral bioavailability (more than 30%), and good ADME characteristics. Multiple enzymes (CYP1A1, 2A6, 2B6, 2C8, CYP 3A4, UGT1A3) biotransform VCH-222. It is expected that VCH-222 is actively transported in the liver and excreted mostly intact in bile or as glucuronide adducts.
Enzyme Assay
VX-222's inhibitory effect on HCV NS5B activity is quantified by measuring the amount of radiolabeled UTP incorporated by the enzyme's C-terminal ∆21 truncated version in a freshly synthesized RNA using a homopolymeric RNA template / primer called poly rA / oligo dT. Liquid scintillation counters are used to quantitatively detect incorporated radioactivity. In vitro kinetics of VX-222-induced inhibition of HCV NS5B from genotype 1b strain BK are ascertained by employing the C-terminal ∆21 truncated form of NS5B. When VX-222 (1 to 1.5 μM) is combined with 0.89 to 6.70 μCi of [α-33P]-labeled UTP and 10 to 75 μM nonradioactive UTP, testing is conducted. 18 minutes at 22 °C are given to RNA-dependent RNA polymerase reactions.
Cell Assay
Trypsinized Huh7.5 cells containing HCV RNA replicons are plated at a density of 4 × 104 cells per well into 48-well plates. The following day, 200 μL of the full medium is added to the new medium along with VX-222. Following a 48-hour period, total RNA is extracted, and real-time reverse transcription-PCR (RT-PCR) is used to quantify viral RNAs. With the use of nonlinear regression analysis and log curve fitting, the effective drug concentrations (EC50) that decreased HCV RNA replicon levels by 50% are determined.
Animal Protocol
Rats or dogs
5 mg/kg for rats or 10 mg/kg for dogs
By oral gavage
References

[1]. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012;56(2):830-837.

[2]. Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates. ACS Med Chem Lett. 2017;8(2):251-255. Published 2017 Jan 31.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C25H35NO4S
Molecular Weight
445.61
Exact Mass
445.23
Elemental Analysis
C, 67.38; H, 7.92; N, 3.14; O, 14.36; S, 7.19
CAS #
1026785-59-0
Appearance
Solid powder
SMILES
CC1CCC(CC1)C(=O)N(C2CCC(CC2)O)C3=C(SC(=C3)C#CC(C)(C)C)C(=O)O
InChi Key
WPMJNLCLKAKMLA-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H35NO4S/c1-16-5-7-17(8-6-16)23(28)26(18-9-11-19(27)12-10-18)21-15-20(13-14-25(2,3)4)31-22(21)24(29)30/h15-19,27H,5-12H2,1-4H3,(H,29,30)
Chemical Name
5-(3,3-dimethylbut-1-ynyl)-3-[(4-hydroxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylic acid
Synonyms
TD-4208; TD4208; GSK-1160724; GSK-1160724; TD 4208; GSK1160724; trade name: Yupelri; TD-4208; GSK 1160724
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~89 mg/mL (~199.7 mM)
Water: <1 mg/mL
Ethanol: <89 mg/mL (~199.7 mM)
Solubility (In Vivo)
30% PEG400+0.5% Tween80+5% propylene glycol: 30 mg/mL
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.2441 mL 11.2206 mL 22.4411 mL
5 mM 0.4488 mL 2.2441 mL 4.4882 mL
10 mM 0.2244 mL 1.1221 mL 2.2441 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00958152 Completed Drug: VCH-222
Drug: telaprevir
Hepatitis C Vertex Pharmaceuticals
Incorporated
May 15, 2021 Phase 1
NCT01581138 Completed Drug: VX-222
Drug: telaprevir
Chronic Hepatitis C Virus Vertex Pharmaceuticals
Incorporated
July 2012 Phase 2
NCT01516918 Completed Drug: VX-222
Drug: telaprevir
Chronic Hepatitis C Virus Vertex Pharmaceuticals
Incorporated
February 2012 Phase 2
NCT00911963 Completed Drug: VCH-222
Drug: ribavirin
Hepatitis C Vertex Pharmaceuticals
Incorporated
January 12, 2018 Phase 1
Phase 2
NCT01581138 Completed Drug: VX-222
Drug: telaprevir
Chronic Hepatitis C Virus Vertex Pharmaceuticals
Incorporated
July 2012 Phase 2
Biological Data
Contact Us